ABVC BioPharma, Inc.
ABVC · NASDAQ
Bulios Fair Price
$0.97
11.0% downside
Current Price
$1.09
According to Bulios Fair Price, ABVC is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
ABVC BioPharma, Inc. is a biotechnology company focused on researching and developing new therapeutic approaches in the fields of oncology and immunotherapy. The company aims to discover drugs that can target specific immune mechanisms and potentially improve the treatment of various types of cancer. ABVC BioPharma strives to bring innovations to cancer treatment and support patients' immune systems in fighting the disease. Their research is directed towards developing drugs that can intervene in complex biological processes associated with cancer. Investors interested in the biotechnology sector and new therapeutic strategies in oncology might see potential in ABVC BioPharma, Inc. (ABVC) shares for innovation and growth in this field.
Sector
Healthcare
Industry
Biotechnology
CEO
Uttam Yashwant Patil
Employees
18
Headquarters
Fremont
Upcoming events
Earnings
Upcoming earnings report